- Drug: Adempas
- Manufacturer: Bayer
- Route of Administration: Oral
- Site of Care: Outpatient
Approved Indication:
- persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and functional class
- pulmonary arterial hypertension (WHO group 1) to improve exercise capacity, improve functional class, and delay clinical worsening
- Disease: chronic thromboembolic pulmonary hypertension, pulmonary arterial hypertension
- Therapeutic Area: Pulmonary
- Enrollment Form Link: www.adempasREMS.com
- Phone Number: 1-855-423-3672
- Fax Number: 1-855-662-5200
- Product Website: adempas.com
